INVO Fertility (IVF) Net Income towards Common Stockholders (2011 - 2026)

INVO Fertility (IVF) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$1.7 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 89.02% year-over-year to -$1.7 million in Q1 2026; TTM through Mar 2026 was -$9.1 million, a 61.39% increase from a year earlier, with the FY2025 full-year figure at -$15.9 million, down 70.24% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$1.7 million, down from $541247.0 in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for IVF reached as high as $541247.0 in Q4 2025 and fell as low as -$15.9 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged -$3.1 million across 5 years, with a median of -$2.5 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders slumped 2818.28% in 2022 and jumped 113.97% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$2.8 million in 2022, then advanced by 28.98% to -$2.0 million in 2023, then sank by 97.15% to -$3.9 million in 2024, then soared by 113.97% to $541247.0 in 2025, then slumped by 422.92% to -$1.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$1.7 million in Q1 2026, $541247.0 in Q4 2025, and -$2.6 million in Q3 2025.